OR WAIT null SECS
© 2021 MJH Life Sciences and BioPharm International. All rights reserved.
© 2021 MJH Life Sciences™ and BioPharm International. All rights reserved.
Contract manufacturers play a key role in the production of lipid nanoparticles for RNA vaccines.
Container and equipment innovations expand applications.
Genetic vaccine platforms demonstrate their potential.
Materials availability is a factor in vaccine production.
June 21, 2021
Advances in technology are accelerating the development and manufacture of subunit vaccines, an established class of vaccines.
RECOVERY trial results have shown that Regeneron’s investigational antibody combination therapy reduces the mortality risk for seronegative hospitalized patients with severe COVID-19.
June 18, 2021
CureVac’s first-generation COVID-19 vaccine candidate, CvnCoV, did not meet efficacy targets in a second interim analysis.
The US government will invest $3 billion from the American Rescue Plan into a COVID-19 antiviral development strategy.
Recent analysis has shown that two doses of COVID-19 vaccines are highly effective against hospitalization as a result of infection with the Delta variant of COVID-19.
June 15, 2021
What can the biopharma industry learn from its rapid response to the COVID-19 pandemic?
Novavax’s COVID-19 vaccine is 90.4% effective and maintains efficacy when administered with an influenza vaccine.
June 14, 2021
The agency approved two batches of drug substance manufactured at the Emergent BioSolutions facility in Baltimore for use in the Janssen COVID-19 vaccine.
June 11, 2021
The new site in Monts, France, which is operated by Recipharm, will produce finished COVID-19 vaccine product.
As a safety measure, supervisory authorities in the European Union have recommended not releasing batches of Janssen’s COVID-19 vaccine with API manufactured at Emergent BioSolutions’ Maryland facility.